| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | PF-232798 Basic information |
| Product Name: | PF-232798 | | Synonyms: | PF-232798;PF 00232798;PF00232798;PF-00232798;PF 232798,PF232798;Acetamide, N-[(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-[4,5,6,7-tetrahydro-2-methyl-5-(2-methyl-1-oxopropyl)-1H-imidazo[4,5-c]pyridin-1-yl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]-;N-[(1S)-1-(3-Fluorophenyl)-3-[(1R,5S)-3-[2-methyl-5-(2-methylpropanoyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridin-1-yl]-8-azabicyclo[3.2. 1]octan-8-yl]propyl]acetamide | | CAS: | 849753-15-7 | | MF: | C29H40FN5O2 | | MW: | 509.66 | | EINECS: | | | Product Categories: | | | Mol File: | 849753-15-7.mol |  |
| | PF-232798 Chemical Properties |
| Boiling point | 765.2±60.0 °C(Predicted) | | density | 1.30±0.1 g/cm3(Predicted) | | pka | 15.39±0.46(Predicted) |
| | PF-232798 Usage And Synthesis |
| Uses | PF-232798 is an orally active CCR5 antagonist with anti-HIV effects[1]. | | References | [1] Ya Zhu, et al. Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5. Acta Pharmacol Sin. 2019 Apr;40(4):563-568. DOI:10.1038/s41401-018-0054-2 |
| | PF-232798 Preparation Products And Raw materials |
|